RMDHIGH SIGNALOPPORTUNITY10-K

RMD delivered exceptionally strong financial performance with a 407% surge in cash reserves to $1.2B and 37% net income growth, while strategically expanding through the VirtuOx acquisition.

The dramatic cash position improvement signals either successful debt refinancing, asset monetization, or exceptional cash generation that far exceeds normal operations. Combined with strong profitability growth and the VirtuOx acquisition expanding their sleep diagnostics capabilities, RMD appears to be in an aggressive growth phase with substantial financial firepower.

Comparing 2025-08-08 vs 2024-08-09View on EDGAR →
FINANCIAL ANALYSIS

RMD's financials show remarkable strength across all metrics, with the most striking being the 407% explosion in cash to $1.2B, accompanied by robust operational performance including 37% net income growth and 25% operating cash flow increase. The company doubled share buybacks to $300M while simultaneously growing total assets 19% to $8.2B, and notably reduced interest expense by 41% despite the growth trajectory. This combination of massive cash accumulation, strong profitability expansion, and balance sheet strengthening suggests either a major strategic pivot or exceptional operational execution that positions the company for significant growth opportunities.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+407.4%
$238.4M$1.2B

Cash position surged 407.4% — strong cash generation or capital raise providing significant financial cushion.

Share Buybacks
Cash Flow
+100%
$150.0M$300.0M

Share repurchases increased 100% — management returning capital, signals confidence in intrinsic value.

Current Assets
Balance Sheet
+48.7%
$2.4B$3.5B

Current assets grew 48.7% — improving short-term liquidity or inventory/receivables build.

Interest Expense
P&L
-40.6%
$40.4M$24.0M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Net Income
P&L
+37.2%
$1.0B$1.4B

Net income grew 37.2% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+27.7%
$1.3B$1.7B

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Operating Cash Flow
Cash Flow
+25%
$1.4B$1.8B

Operating cash flow grew 25% — strong conversion of earnings to cash, healthy business fundamentals.

Stockholders Equity
Balance Sheet
+22.7%
$4.9B$6.0B

Equity base grew 22.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Total Assets
Balance Sheet
+18.9%
$6.9B$8.2B

Asset base grew 18.9% — expansion through organic growth, acquisitions, or capital deployment.

Gross Profit
P&L
+15.1%
$2.7B$3.1B

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

LANGUAGE CHANGES
NEW — 2025-08-08
PRIOR — 2024-08-09
ADDED
At August 4, 2025, the registrant had 146,414,839 shares of Common Stock, $0.004 par value, issued and outstanding.
This number excludes 43,925,747 shares held by the registrant as treasury shares.
We also provide management software that assists durable or home medical equipment (DME/HME) providers, and other long-term care providers operate more effectively and efficiently across various residential care settings.
In May 2025, we acquired VirtuOx, a software-enabled independent diagnostic testing facility, or IDTF, and provider of technology solutions to facilitate in-home and remote testing services for sleep, respiratory, cardiac, and other health conditions across the United States, or U.S.
This acquisition strengthens our position in the sleep and breathing health market by expanding our ability to offer end-to-end solutions, including home-based diagnostics and patient monitoring.
+7 more — sign up free →
REMOVED
At August 5, 2024, the registrant had 146,932,119 shares of Common Stock, $0.004 par value, issued and outstanding.
This number excludes 42,664,067 shares held by the registrant as treasury shares.
We also provide management software to agencies providing OOH care, including but not limited to home medical equipment, or HME, home health and hospice, skilled nursing, life plan community, senior living, outpatient therapy and private duty services.
AND SUBSIDIARIES We employ over 9,980 people and sell our products in over 140 countries through a combination of wholly owned subsidiaries and independent distributors.
Segment Information We operate in two segments, which are the Sleep and Respiratory Care segment and the Software as a Service, or SaaS, segment.
+7 more — sign up free →
MORE OPPORTUNITY SIGNALS
IRIXHIGHIRIX demonstrated a dramatic operational turnaround with revenue surging 283% wh...
2026-04-02
CSAIHIGHCSAI underwent a dramatic financial transformation with revenue growing 271% to ...
2026-03-31
PLMKWHIGHPLMKW has entered into a definitive business combination agreement with Controll...
2026-03-31
LXEOHIGHLXEO achieved significant clinical milestones with positive interim data and reg...
2026-03-30
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →